Lv2
116 积分 2021-06-11 加入
Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia
18天前
已完结
Transforming obesity: The advancement of multi-receptor drugs
26天前
已完结
An updated patent review of GLP-1 receptor agonists (2020-present)
26天前
已完结
Definition and diagnostic criteria of clinical obesity
27天前
已完结
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
1个月前
已完结
Mechanisms and regulation of cholesterol homeostasis
1个月前
已完结
New and Emerging Therapies for Dyslipidemia
1个月前
已完结
Protecting against fatty liver disease
1个月前
已完结
Epigenome editing technologies for discovery and medicine
2个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2个月前
已完结
皖公网安备34019202002308
